A new Gastropanel quick test for non-invasive diagnosys in dyspeptic patients. The first experience in primary care setting in North East Italy
Keywords:
DyspepsiaQuick Gastropanel test, Pepsinogens, Gastrin 17, Atrophic GastritisAbstract
Background: Gastropanel is a non-invasive serological test based on Pepsinogens, Gastrin 17, IgG against Hp.
Aim of the study: To assess the clinical usefulness of a new quick gastropanel test in a sample of dyspeptic patients in primary care setting.
Methods: The GastroPanel® quick test (Biohit Finland), is a rapid lateral flow immunochromatographic POCT test. The results could be available in fifteen minutes.
Patient's Population: One hundred and eighty-eight (76 M, 112 F) dyspeptic patients were investigated by using serum pepsinogens, gastrin 17 and IgG against (quick Gastropanel Test).
Results: Patients were singled out as follows: 1) Functional Dyspepsia (72 pts); 2) GERD (40 pts) 3) GERD under PPIs (37 pts), 4) Non-Atrophic Gastritis Hp + (29 pts), 5 Autoimmune Atrophic Gastritis (6 pts), 6) Multifocal Atrophicc Gastritis (4 pts). PGI: the greatest increase in patients on PPIs therapy (148.1 mg/L; p<0.0001), a more moderate increase in Hp patients (116.8 mg/L; p<0.001 and a significant decrease in AAG groups (29.4 mg/L; p<0.0001) and MAG (28.5 mg/L; p<0.0001). PGII: an increase in PPIs users (28.2 mg/L; p<0.001) and in Hp positive subjects (26.0 mg/L; p<0.001). G17: low in GERD subjects (1.8 pmol/L; p<0.01). Subjects on PPIs show elevated levels (15.7 pmol/L; p<0.0001). Patients with AAG show increased G17 (9.2 pmol/L; p<0.05), MAG subjects show low levels (2.0 pmol/L; p<0.01).
Conclusion: This study show that the new quick gastropanel test is a reliable method also in a non-laboratory setting. Therefore, it could be proposed as the first approach in primary care.
References
1. Stanghellini V. Functional dyspepsia and irritable bowel syndrome: Beyond Rome IV. Dig Dis. 2017;35(Suppl 1):14-7. doi:10.1159/000485408
2. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380-92. doi:10.1053/j.gastro.2016.02.011
3. Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;S0016-5085(16)00223-7. doi:10.1053/j.gastro.2016.02.032 [INCOMPLETE]
4. Malfertheiner P, Megraud F, O’Morain C, et al. Management of Helicobacter pylori infection: The Maastricht V/Florence consensus report. Gut. 2017;66:6-30. [INCOMPLETE]
5. Malfertheiner P, Megraud F, Rokkas T, et al. European Helicobacter and Microbiota Study Group. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut. 2022;gutjnl-2022-327745. doi:10.1136/gutjnl-2022-327745
6. Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: Diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46:1-11. doi:10.1111/apt.14248
7. Crafa P, Franceschi M, Rodriguez Castro KI, et al. Functional dyspepsia. Acta Biomed. 2020;91(3):e2020069. doi:10.23750/abm.v91i3.10150
8. Sipponen P, Vauhkonen M, Helske T, et al. Low circulating levels of gastrin-17 in patients with Barrett’s esophagus. World J Gastroenterol. 2005;11:5988-92. doi:10.3748/wjg.v11.i38.5988
9. Di Mario F, Franzoni L, Franceschi M, et al. Low levels of G17 and Barrett esophagus: A clinical relationship. Clin Chem Lab Med. 2022;60(7):e165-e7. doi:10.1515/cclm-2022-0362
10. Di Mario F, Crafa P, Franceschi M, et al. Low levels of gastrin-17 are related with endoscopic findings of esophagitis and typical symptoms of GERD. J Gastrointestin Liver Dis. 2021;30(1):25-9. doi:10.15403/jgld-2952
11. Chhabra M, Kolatkar A, Chawla S, et al. Point-of-care diagnosis of atrophic gastritis by serological biomarker test (GastroPanel Quick Test) in gastroscopy referral patients in India. J Clin Med. 2025;14(3):787. doi:10.3390/jcm14030787
12. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. doi:10.1136/gutjnl-2015-309252
13. Rugge M, Genta RM, Malfertheiner P, et al. RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut. 2024;73(3):407-41. doi:10.1136/gutjnl-2023-331164
14. Di Mario F, Crafa P, Barchi A, et al. Pepsinogen II in gastritis and Helicobacter pylori infection. Helicobacter. 2022;27(2):e12872. doi:10.1111/hel.12872
15. Papadia C, Marelli L, Wood E, et al. Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study. BMJ Open Gastroenterol. 2025;12(1):e001559. doi:10.1136/bmjgast-2024-001559
16. Syrjänen K. Accuracy of serum biomarker panel (GastroPanel) in diagnosis of atrophic gastritis of the corpus. Anticancer Res. 2022;42:1679-96. doi:10.21873/anticanres.15645
17. Chapelle N, Petryszyn P, Blin J, et al. A panel of stomach-specific biomarkers (GastroPanel) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area. Helicobacter. 2020;25:e12727. doi:10.1111/hel.12727
18. Storskrubb T, Aro P, Ronkainen J, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol. 2008;43(12):1448-55. doi:10.1080/00365520802273025
19. Venerito M, Radünz M, Reschke K, et al. Autoimmune gastritis in autoimmune thyroid disease. Aliment Pharmacol Ther. 2015;41(7):686-93. doi:10.1111/apt.13097
20. Rugge M, Bricca L, Guzzinati S, et al. Autoimmune gastritis: Long-term natural history in naïve Helicobacter pylori-negative patients. Gut. 2023;72(1):30-8. doi:10.1136/gutjnl-2022-327827
21. Russo M, Rodriguez-Castro KI, Franceschi M, et al. Appropriateness of proton pump inhibitor prescription evaluated by using serological markers. Int J Mol Sci. 2023;24(3):2378. doi:10.3390/ijms24032378
22. Koivurova OP, Koskela R, Blomster T, et al. Serological biomarker panel in diagnosis of atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients: Clinical validation of the new-generation GastroPanel test. Anticancer Res. 2021;41:5527-37. doi:[INCOMPLETE]
23. Biohit HealthCare. GastroPanel [Internet]. Available from: https://www.biohithealthcare.com/en/products/gastropanel-elisa/ [accessed 2024 Oct 23]
24. Biohit HealthCare. GastroPanel Quick Test NT [Internet]. Available from: https://www.biohithealthcare.com/en/products/gastropanel-quick-test-nt/ [accessed 2024 Oct 23]
25. Biohit HealthCare. GastroPanel Quick Test NT user guide [Internet]. Available from: https://www.biohithealthcare.com/wp-content/uploads/2023/12/GPQTNT_402230en_2.1_UG_FINAL_20231219.pdf [accessed 2024 Oct 23]
26. Syrjänen K, Eskelinen M, Peetsalu A, et al. GastroPanel biomarker panel: The most comprehensive test for Helicobacter pylori infection and its clinical sequelae. Anticancer Res. 2019;39:1091-104.
27. Biohit HealthCare. GastroPanel [Internet]. Available from: https://www.gastropanel.com/healthcare-professionals-and-laboratories/forms-and-instructions [accessed 2024 Oct 23]
28. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis: The updated Sydney system. Am J Surg Pathol. 1996;20:1161-81.
29. Sipponen P, Price AB. The Sydney system for classification of gastritis 20 years ago. J Gastroenterol Hepatol. 2011;26(Suppl 1):31-4.
30. Koivurova OP, Ukkola O, Koivikko M, et al. Screening of patients with autoimmune thyroid disease and type 1 diabetes mellitus for atrophic gastritis by serological biomarker testing (GastroPanel). EC Gastroenterol Dig Syst. 2020;7:181-95. [INCOMPLETE]
31. Mäki M, Söderström D, Paloheimo L, et al. Helicobacter pylori IgG ELISA of the new-generation GastroPanel is highly accurate in diagnosis of Hp infection in gastroscopy referral patients. Anticancer Res. 2020;40:6387-98.
32. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: A tutorial. Dig Liver Dis. 2008;40(8):650-8. doi:10.1016/j.dld.2008.02.030
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Francesco Di Mario, Marilisa Franceschi, Kryssia Isabel Rodriguez Castro, Lorella Franzoni, Cecilia Panizza, Roberto Vano, Francesca Gombac, Antonio Tursi, Giovanni Brandimarte, Pellegrino Crafa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
